pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,139 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints775BioPharma Dive297BioSpace214Fierce Biotech203onclive165raps74globenewswire health
therapy area
allOncology6025Rare Disease1434Cardiology1089Hematology1024Immunology998Vaccines901Pulmonology
  • STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
    An international team has found thousands of mini-proteins, including some involved in cell division and DNA repair, as well as several unique to cancer cells.
    STAT · 3mo ago↗ source
  • STAT+: When the path to good AI is littered with bad data
    In this edition of AI Prognosis, Brittany Trang raises the question: What kind of health data would we need to train AI models to be useful in health care.
    STAT · 3mo ago↗ source
  • ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
    Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
    onclive · 3mo ago
← prev
page 76 of 86
next →
73
fda recalls47
fda medwatch37
fda press28
899
Psychiatry & CNS712
Ophthalmology421
Endocrinology & Metabolism380
Pain373
Infectious Disease353
↗ source
  • GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
    GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzho…
    Endpoints · 3mo ago↗ source
  • STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
    Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
    One of the most powerful pharmaceutical lobbying groups is launching a new seven-figure advertising blitz targeting a federal drug discount program
    STAT · 3mo ago↗ source
  • Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management
    Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.
    onclive · 3mo ago↗ source
  • Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration
    New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
    onclive · 3mo ago↗ source
  • Disease Assessment and Mutational Testing in Progressive CLL
    Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.
    onclive · 3mo ago↗ source
  • Clinical Scenario Presentation and Treatment Approach for Progressive Disease
    Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.
    onclive · 3mo ago↗ source
  • Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
    Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.
    onclive · 3mo ago↗ source
  • Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026
    SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.
    onclive · 3mo ago↗ source
  • HHS tackles ‘overmedication’
    The cruise ship hantavirus outbreak, 988 staffing problems, and more health news from Morning Rounds
    STAT · 3mo ago↗ source
  • CellCentric raises $220M to get multiple myeloma pill to market
    CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…
    Endpoints · 3mo ago↗ source
  • Bayer to buy Perfuse Therapeutics for $300M upfront
    Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…
    Endpoints · 3mo ago↗ source
  • Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
    A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…
    Endpoints · 3mo ago↗ source
  • Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia care
    Ambiguous loss is at the heart of the dementia illness experience.
    STAT · 3mo ago↗ source
  • Opinion: Dr. Glaucomflecken wants to make a stink
    “They don’t want this kind of scrutiny”: Why Dr. Glaucomflecken is getting involved in protests over an Oregon hospital system’s emergency department.
    STAT · 3mo ago↗ source
  • STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
    Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
    STAT · 3mo ago↗ source
  • STAT+: OpenAI wants to ‘have their cake and eat it too’ with health AI policy recommendations
    Policy recommendations in OpenAI's blueprint for unlocking AI’s potential to change health care are reasonable, but also self-serving, experts say.
    STAT · 3mo ago↗ source
  • Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
    The psychedelics field is getting what it has long wanted. Now it has to step up.
    STAT · 3mo ago↗ source
  • Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC
    Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.
    onclive · 3mo ago↗ source
  • Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
    Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.
    onclive · 3mo ago↗ source
  • STAT+: Did AI really beat doctors at diagnosis?
    In this edition of STAT Health Tech: A high-profile study on AI's diagnostic capabilities, role of telehealth in abortion access, and an Epic lawsuit.
    STAT · 3mo ago↗ source
  • Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
    Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.
    onclive · 3mo ago↗ source